m-lab GmbH is a spin-off from the University of Mainz, Germany. We are developing and commercializing innovative point-of-care n(POC) devices and personalized treatment approaches in Ophthalmology. The initial product, a Glaucoma diagnostic platform, will provide early detection of Glaucoma, the most prevalent cause of blindness in the world today, by means of an affordable, easy-to- se, point-of-care test, yielding a Glaucoma Risk Score within a few minutes independent from specialized laboratories and ophthalmologists. We foresee a yearly test at below €20 for all people aged over 50 years.
Deck: https://1drv.ms/p/s!AgZt8Zs5eVaZ4JIpoYL2wLPLjM35fQ?e=7q8tU8
Video: https://vimeo.com/831180226/eabef5b968
The test is based on m-lab’s innovative highly sensitive multiplexing lateral flow platform detecting disease specific marker patterns in tear fluid with a reader and combined smartphone reader software for A.I. based disease scoring. This will be at present the only POC diagnostics for glaucoma independent from any additional instrumention and which can be done everywhere by anybody.
After final prototype optimization and licencing of the Glaucoma test system, we expect to launch the diagnostic platform within the next 2 years.
In parallel, we are continuously developing our therapeutic antibody program, with the aim of developing urgently needed new neuroprotective treatment options to prevent blindness.
Board and Team:
Prof. Dr. Dr. F. Grus: Head of Translational and Experimental Ophthalmology at University of Mainz and CEO m-lab
Prof. Dr. Norbert Pfeiffer: Co-Founder of m-lab and CEO of University Medical Center of Mainz and member of Leopoldina
Dr. Dominik Beck: Board Member and Advisor to Managing Director, Experienced leader (CEO/COO/President/GM) in the medical device and pharma like Haag-Streit, Alcon, Iridex, DORC
Dr. Frank Seibel: Co-Founder and specialist in distribution and marketing of ophthamological products
ISB (Investitions- und Strukturbank Rheinland-Pfalz)
Dr. Peter Taylor: Specialist in developing lateral flow assays for decades
Scientists: Julia Sann and Janis Heyne
Bio-Informatics: Dominik Wolters (A.I. and reader app)
Technicians and students